CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
www.creativemedicaltechnology.comAI Executive Summary
AI-powered analysis of 10-K filing content
Creative Medical Technology Holdings shows deteriorating financial performance with increasing losses ($6.1M in 2025 vs $5.7M in 2024), minimal revenue generation ($6K in 2025 vs $11K in 2024), and high cash burn rate. Despite FDA approvals for clinical trials, the company faces significant funding challenges with only $7.2M cash remaining against $5.9M annual burn rate.
Red Flags Detected (6)
Operating losses increased 7% to $6.1 million in 2025
Revenue declined 45% from $11K to $6K year-over-year
High cash burn rate of $5.9 million annually with only $7.2 million remaining
3 more red flags detected
Key Takeaways
Company has less than 15 months of cash runway at current burn rate
Clinical trials for Type I Diabetes and chronic back pain are FDA-approved but will increase expenses
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.